top of page
Browse by category
Search
Endoscopic sleeve gastroplasty an effective alternative therapy for MASH
Endoscopic sleeve gastroplasty (ESG) may be an effective alternative therapy in the treatment of patients with metabolic...
MBS patients have a greater risk for multiple cancer types compared with the general population
All-cancer incidence risk is similar between patients who underwent metabolic and bariatric surgery (MBS) and the general population,...
Bariatric patients have lower healthcare costs vs non-surgical counterparts out to five years
Bariatric surgery can save patients thousands of dollars in health care costs over the long run, according to research from Duke...
Researcher 2 Researcher and Bariatric News - The Podcasts
Spend an engaging hour with Researcher 2 Researcher and Bariatric News as we explore a range of topics in Bariatric and Metabolic...
Pouch revision plus raRYGB is a promising approach for recurrent weight gain
Pouch revision in combination with ring-augmented Roux-en-Y gastric bypass (raRYGB) – using a MiniMizer Ring - appears to be a promising...
Considerations when moving from laparoscopic to robotic assisted bariatric surgery
At the recent IFSO-EC meeting in Venice, Italy, Medtronic hosted an intriguing lunch time symposium that examined the technical and...
BOMSS changes name to include all obesity specialists
Bariatric News spoke with Professor Ahmed Ahmed (Associate Professor in Metabolic Surgery and Lead Bariatric Surgeon at Imperial College...
Ring-augmented RYGB in patients with BMI≥50 leads to significant weight loss and improvement in obesity-related complications
Ring-augmented RYGB (raRYGB) with a MiniMizer Ring in patients with BMI≥50kg/m2, results in significant weight loss and improvements in...
International expert consensus statements on surgery for T2DM
An International panel of experts has published 43 statements on the nature, terminology and mechanisms of action of metabolic and...
Only one in 12 remain on a GLP-1 drug for obesity at three years
Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to...
Browse by tag
bottom of page